We serve Chemical Name:6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one CAS:304861-88-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one](https://a.dearchem.com/CAS2/304861-88-9.png)
Chemical Name:6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one
CAS.NO:304861-88-9
Synonyms:6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one
Molecular Formula:C6H4ClN3O
Molecular Weight:169.56800
HS Code:2933990090
Physical and Chemical Properties:
Melting point:338-340℃
Boiling point:N/A
Density:1.82
Index of Refraction:
PSA:61.54000
Exact Mass:169.00400
LogP:0.90460
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one Use and application,6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one technical grade,usp/ep/jp grade.
Related News: From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one manufacturer The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD. 6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one supplier Government prosecutors often consider whether a corporation made a genuine effort to investigate and address potentially illegal activities once learning of them. 6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one vendor From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 6-chloro-1,3-dihydroimidazo[4,5-b]pyridin-2-one factory In approving the first new Alzheimer’s drug in nearly 20 years, the U.S. Food and Drug Administration is taking its biggest risk yet with a strategy that allows new therapies onto the market without strong evidence that they work, regulatory and scientific experts say.
